Aspen And Mylan Strike A Deal On Australia And New Zealand Portfolio

Mylan has bolstered its presence in key Australasian markets through a portfolio distribution arrangement with Aspen Pharma, which includes an option to buy in March 2019; the South African firm, on the other hand, is continuing to manage its portfolio in the markets, “allowing enhanced operational focus and removing complexity.”